Clinical Trial Update: A Study to Assess an ATX Inhibitor (IOA-289) in Patients With Metastatic Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

This entry documents the completion of a Phase 1/2 clinical trial evaluating IOA-289, an ATX inhibitor from iOnctura, in patients with metastatic pancreatic can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• IOA-289

Snippet

Sponsor: iOnctura | Conditions: Metastatic Pancreatic Cancer | Phase 1, Phase 2 | Status: COMPLETED